DEA Proposes 365-Day Reexport Window for Controlled Substances

DEA Proposes to Double Reexport Period for Controlled Substances

On October 1, 2026, the U.S. Drug Enforcement Administration (DEA) published a proposed rule in the Federal Register to extend the allowable period for reexporting controlled substances outside the European Economic Area (EEA) from 180 days to 365 days. This change, if adopted, would amend DEA regulations to give exporters and researchers nearly twice as long to move controlled substances—including psychedelic compounds—through international supply chains before violating reexport deadlines. The proposal is open for public comment and, if finalized, would affect U.S. exporters, international research partners, and pharmaceutical manufacturers handling substances under DEA oversight.

Mechanism and Context: How the Rule Alters Global Supply Chains

The proposed rule directly impacts the logistics of international controlled substance shipments by extending the reexportation window. Under current DEA regulations, companies must ensure that controlled substances shipped from the United States to non-EEA countries are reexported within 180 days of release from U.S. Customs and Border Protection. The proposed amendment would extend this period to 365 days, reducing the risk of inadvertent regulatory violations due to shipping delays, customs holds, or complex trial site coordination.

This change is particularly relevant for pharmaceutical and research organizations working with Schedule I and II substances, such as psilocybin, LSD (lysergic acid diethylamide), and MDMA (3,4-methylenedioxymethamphetamine), which are increasingly the subject of multinational clinical trials and manufacturing agreements. The extension could also benefit contract research organizations (CROs) and global partners managing multi-site studies, as it allows for greater flexibility in coordinating shipments and regulatory paperwork across jurisdictions with varying import requirements.

One non-obvious implication is that the new rule may encourage more U.S.-based firms to act as central suppliers for international studies, reducing reliance on third-country intermediaries and potentially improving oversight and chain-of-custody documentation—a key concern in regulatory audits.

Policy and Research Implications for Psychedelic Science

The DEA's proposed extension does not alter the legal status or domestic scheduling of psychedelics and other controlled substances, nor does it change the requirements for obtaining export or import permits. However, it does address a practical bottleneck faced by many organizations navigating the complex regulatory environment for international research and drug development.

For clinical trials involving psychedelics, where delays in site activation or regulatory approvals are common, the longer reexport window may reduce the risk of expired authorizations and wasted materials. This could facilitate smoother timelines for global studies, especially those involving multiple countries with asynchronous regulatory reviews. Pharmaceutical companies and academic institutions may also find it easier to manage inventory and compliance when shipping reference standards, investigational drugs, or comparator substances across borders.

Importantly, the rule may also help U.S. entities maintain competitiveness in the emerging global psychedelics industry, as tighter reexport windows have previously led some sponsors to prefer European or Canadian suppliers with more flexible timelines.

Risks, Unknowns, and Compliance Considerations

While the extension of the reexportation period offers logistical benefits, it introduces new compliance challenges. Companies must still track and document the movement of controlled substances meticulously, as any lapse beyond the 365-day window could trigger enforcement actions or jeopardize future export privileges. The rule does not relax requirements for import permits, end-user certifications, or reporting obligations in the receiving country.

There is also the risk that longer storage or transit times could increase opportunities for diversion or loss, especially in jurisdictions with weaker regulatory controls. DEA and international partners may require enhanced chain-of-custody documentation or periodic audits to mitigate these risks. Additionally, the effectiveness of the rule will depend on harmonization with foreign regulators, who may have their own timelines or restrictions that do not align with U.S. policy.

For organizations unfamiliar with the nuances of U.S. export law, the extended window could create a false sense of security if not paired with robust compliance training and real-time shipment tracking. The DEA has not indicated whether it will provide additional guidance or resources for exporters adapting to the new rule.

Looking Forward: Global Collaboration and Regulatory Evolution

If finalized, the DEA's proposal to extend the reexportation period for controlled substances to 365 days could mark a significant step in aligning U.S. regulatory practice with the realities of global drug development and research. By reducing logistical friction, the rule may facilitate more robust international collaboration, particularly in the fast-evolving field of psychedelic science.

Stakeholders should monitor the rulemaking process and prepare to update internal protocols if the extension is adopted. The change could influence supply chain strategies, site selection for clinical trials, and the role of U.S. firms in the international psychedelics market. However, success will depend on continued vigilance in compliance and proactive engagement with both U.S. and foreign regulators as cross-border research accelerates.

How we research: This article was written and reviewed by Dr. Alex Grant, PhD (policy editor, Psychedelic Research Journal), on 2026-10-02. Sources include the official DEA rule proposal in the Federal Register and direct agency guidance.